...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Efficacy of combined androgen blockade with zoledronic acid treatment in prostate cancer with bone metastasis: The ZABTON-PC (zoledronic acid/androgen blockade trial on prostate cancer) study
【24h】

Efficacy of combined androgen blockade with zoledronic acid treatment in prostate cancer with bone metastasis: The ZABTON-PC (zoledronic acid/androgen blockade trial on prostate cancer) study

机译：雄激素联合唑来膦酸治疗前列腺癌伴骨转移的疗效：ZABTON-PC（唑来膦酸/雄激素对前列腺癌的阻断试验）研究

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aim: Zoledronic acid (ZA) reduces the risk of skeletal-related events (SREs) in castration-resistant prostate cancer (CRPC) with bone metastasis and improves quality of life. It remains unclear when clinicians should initiate ZA treatment. Patients and Methods: Hormone-na?ve patients were randomized to a combined androgen blockade (CAB) group or CAB with ZA group (CAB-ZA) based on Gleason score (GS) or extent of disease. The primary end-point of the study was progression-free survival (PFS) and the secondary end-point was incidence of SREs and bone pain. Results: Thirty-one and 29 patients among 60 enrolled patients were assigned to the CAB group and the CAB-ZA group, respectively. There was no significant difference in PFS between the two groups. Subgroup analyses revealed better PFS in the CAB-ZA group with GS ≥8 (p=0.021). Moreover, incidence of SREs, including bone pain, was lower in the CAB-ZA group (p=0.019). Conclusion: CABZA treatment was found to improve PFS for patients with prostate cancer with high GS. CAB-ZA treatment could be recommended for treatment of patients with prostate cancer.
机译：目的：唑来膦酸（ZA）可降低去势抵抗性前列腺癌（CRPC）中发生骨转移的骨骼相关事件（SRE）的风险，并改善生活质量。目前尚不清楚临床医生何时应该开始ZA治疗。患者和方法：根据Gleason评分（GS）或疾病程度，将未接受过激素治疗的患者随机分为联合雄激素阻断（CAB）组或CAB与ZA组（CAB-ZA）。该研究的主要终点是无进展生存期（PFS），次要终点是SRE和骨痛的发生率。结果：60名入选患者中的31名和29名患者分别被分为CAB组和CAB-ZA组。两组之间的PFS没有显着差异。亚组分析显示，GS≥8的CAB-ZA组的PFS更好（p = 0.021）。此外，CAB-ZA组的SRE发生率（包括骨痛）较低（p = 0.019）。结论：发现CABZA治疗可改善高GS前列腺癌患者的PFS。 CAB-ZA治疗可推荐用于前列腺癌患者的治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号